List of Excipients in Branded Drug ZETONNA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Covis Pharma US Inc	ZETONNA	ciclesonide	70515-737	ALCOHOL	2028-02-01
Covis Pharma US Inc	ZETONNA	ciclesonide	70515-737	NORFLURANE	2028-02-01

Zetonna Excipient Strategy and Commercial Opportunities for Ciclesonide Nasal Aerosol

Last updated: October 4, 2026

Zetonna is a metered-dose nasal aerosol containing ciclesonide, an inhaled corticosteroid used for seasonal and perennial allergic rhinitis. Its excipient platform is unusually simple: ciclesonide is delivered from a pressurized hydrofluoroalkane-134a propellant system with ethanol as the principal co-solvent. The commercial opportunity is less likely to come from copying the original formulation than from developing a lower-impact propellant, improving nasal deposition, reducing device cost, or extending ciclesonide into combination and pediatric products.

The principal technical barriers are aerosol plume control, dose uniformity, valve performance, extractables and leachables, microbial control without conventional preservatives, and demonstration of equivalent local delivery. Generic competition must address the complete drug-device combination rather than only the active ingredient.

What is Zetonna and how is it formulated?

Zetonna contains ciclesonide at 37 micrograms per actuation. The approved product is a nasal aerosol supplied in a pressurized canister and actuator. It is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 12 years of age and older.[1]

Product attribute	Zetonna profile
Active ingredient	Ciclesonide
Dosage form	Metered-dose nasal aerosol
Strength	37 mcg per spray
Route	Intranasal
Principal excipients	HFA-134a propellant and ethanol
FDA approval	2012
Original NDA	NDA 202535
Reference company	Sunovion Pharmaceuticals
Main indication	Seasonal and perennial allergic rhinitis
Administration	One spray per nostril once daily in the approved labeling
Device type	Pressurized metered-dose nasal delivery system

The absence of a conventional aqueous phase and preservative system differentiates Zetonna from most intranasal corticosteroid products. Many competing products, including fluticasone, mometasone and budesonide nasal sprays, use aqueous suspensions or solutions delivered through mechanical pump systems.

Ciclesonide is a prodrug converted locally to desisobutyryl-ciclesonide, its active metabolite. The prodrug approach can support local anti-inflammatory activity with limited systemic exposure, although clinical performance depends on nasal deposition, mucosal retention and formulation release.[1,2]

What excipients does Zetonna use?

Zetonna uses HFA-134a and ethanol as its disclosed inactive ingredients. HFA-134a provides the vapor pressure needed to expel the formulation. Ethanol functions as a co-solvent and can influence ciclesonide solubility, plume characteristics, evaporation rate and deposited droplet size.[1]

HFA-134a

HFA-134a, also known as 1,1,1,2-tetrafluoroethane, replaced chlorofluorocarbon propellants in many pharmaceutical aerosols. It has established pharmaceutical use, extensive toxicology history and well-characterized compatibility with metering valves and aluminum canisters.

Its commercial weaknesses are environmental and supply related. HFA-134a has a high global-warming potential compared with emerging propellants. Pharmaceutical metered-dose inhalers are being evaluated for transition to lower-global-warming-potential propellants under national and international climate policies. Nasal products are likely to face similar pressure as regulators and manufacturers standardize aerosol platforms.

Ethanol

Ethanol is the formulation’s principal solvency and performance modifier. Changes in ethanol concentration can affect:

• Ciclesonide solubility and precipitation risk.
• Spray force and plume geometry.
• Droplet or particle evaporation.
• Nasal irritation and tolerability.
• Dose uniformity over canister life.
• Valve metering behavior.
• Container closure compatibility.

A generic manufacturer cannot treat ethanol as an interchangeable processing solvent. Its concentration is likely to be a critical quality attribute because it directly affects delivered dose and regional nasal deposition.

What Zetonna does not appear to require

The approved formulation does not rely on an aqueous vehicle, benzalkonium chloride, phenylethyl alcohol or a conventional suspending agent. That simplifies microbial-control requirements and avoids some preservation-related tolerability issues. It also creates a narrower formulation design space because the product depends heavily on the interaction among drug, ethanol, propellant, valve and actuator.

How does Zetonna compare with aqueous nasal corticosteroids?

Zetonna competes against lower-cost aqueous nasal sprays but offers a different delivery platform.

Attribute	Zetonna	Typical aqueous corticosteroid spray
Propulsion	Pressurized HFA aerosol	Manual pump
Vehicle	Non-aqueous	Water-based
Preservative requirement	Generally reduced	May be required depending on package
Dose delivery	Metered valve	Mechanical pump
Device complexity	Higher	Lower
Formulation risk	Propellant, valve and plume control	Suspension or solution stability
Environmental issue	Propellant global-warming potential	No propellant
Generic development	Drug-device equivalence	Primarily formulation and pump equivalence
Patient handling	Requires aerosol actuation technique	Requires pump priming and actuation

The commercial rationale for the aerosol platform is strongest where plume control, low spray volume, reduced dripping or differentiated patient experience produces measurable adherence or preference benefits. Without such differentiation, an HFA nasal aerosol carries higher manufacturing and environmental costs than a pump spray.

What excipient strategies could improve Zetonna or support a generic?

Lower-global-warming-potential propellants

The most important long-term strategy is evaluation of HFA-152a or HFO-1234ze(E). These propellants may reduce climate impact, but substitution is not a simple one-for-one change. Each candidate can alter:

• Vapor pressure.
• Solvent strength.
• Drug solubility.
• Canister pressure.
• Actuator plume.
• Valve elastomer swelling.
• Dose content uniformity.
• Flammability classification.
• Manufacturing and transport controls.

HFA-152a is flammable and may require modified facility controls, packaging procedures and shipping assessments. HFO-1234ze(E) has a different vapor-pressure profile and may require a reformulated ethanol ratio or redesigned actuator.

A commercially viable replacement must preserve the emitted-dose profile and nasal deposition of the reference product while meeting updated environmental expectations.

Ethanol optimization

Ethanol concentration can be optimized to balance solubility, plume behavior and tolerability. A lower concentration may reduce irritation and flammability concerns, but can increase crystallization or dose nonuniformity. A higher concentration may improve solubilization while increasing evaporation effects and local stinging.

The preferred formulation should be screened across temperature, orientation, storage time and canister life. Stability studies should include assay, impurities, delivered dose uniformity, spray content uniformity, plume geometry and particle-size distribution.

Alternative valve and actuator systems

The valve and actuator are part of the product’s performance profile. Commercial improvements may include:

• Lower-cost metering valves.
• Reduced residual volume.
• Improved priming performance.
• More consistent actuation force.
• Dose counters.
• Actuation-lock features.
• Geometry that limits oropharyngeal deposition.
• Actuators optimized for pediatric hand strength.

A redesigned actuator can create a defensible device patent position even when active-ingredient protection has expired. The design must remain clinically and pharmaceutically equivalent to the reference product where an abbreviated regulatory pathway is used.

Canister and coating selection

Aluminum canisters with internal coatings may reduce adsorption, corrosion or extractables. Ciclesonide and ethanol compatibility should be assessed with:

• Bare aluminum.
• Epoxy or fluoropolymer coatings.
• Elastomer valve components.
• Lubricants.
• Adhesives.
• Plastic actuator materials.

Extractables and leachables are particularly relevant because the drug is stored in direct contact with the formulation for the full shelf life. A lower-cost canister that increases impurity formation can eliminate the expected commercial margin.

What generic entry risks exist for Zetonna?

The principal generic risk is technical rather than purely chemical. A ciclesonide nasal aerosol applicant must usually demonstrate pharmaceutical equivalence and device-related performance. Critical development work includes:

1. Matching strength and metered dose.
2. Demonstrating delivered-dose uniformity.
3. Characterizing aerodynamic or spray particle-size distribution.
4. Establishing plume geometry and spray pattern.
5. Demonstrating priming and repriming behavior.
6. Controlling residual drug and canister life.
7. Assessing local tolerability.
8. Establishing container-closure integrity.
9. Addressing extractables and leachables.
10. Supporting bioequivalence through FDA-accepted comparative methods.

FDA guidance for nasal spray and inhalation products emphasizes product performance, device operation and local delivery characteristics, not only assay and dissolution.[3,4]

The generic opportunity is stronger if the reference product has limited current supply or a weak commercial presence. The development risk is higher than for an aqueous pump spray because the applicant must reproduce a pressurized formulation and device system.

What patents protect Zetonna and when does it lose exclusivity?

Zetonna’s core ciclesonide composition and formulation protection originated from the broader ciclesonide patent estate. The relevant commercial rights historically included active-ingredient, formulation, aerosol-delivery and method-of-use claims. Patent status must be evaluated by claim family and jurisdiction because expiration dates differ across U.S., European and other national rights.

The FDA Orange Book is the controlling source for current U.S. listed patents and regulatory exclusivity associated with the NDA.[5] A commercial assessment should distinguish:

Protection category	Relevance to Zetonna
Active-ingredient patents	Broad ciclesonide protection; generally the oldest rights
Formulation patents	Ethanol-propellant ratios, concentration, stability or aerosol performance
Device patents	Metering valve, actuator, canister or dose-counter architecture
Method-of-use patents	Allergic rhinitis treatment, dosing schedules or patient populations
Regulatory exclusivity	NDA-based protection separate from patent term
Manufacturing patents	Filling, crimping, pressure control and product testing

The original 2012 approval does not itself establish a current patent barrier. Pharmaceutical patent terms are generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any patent-term extension. A precise launch date requires review of the current Orange Book, relevant patent families and litigation records.[5,6]

Are Paragraph IV challenges likely?

A Paragraph IV challenge is technically plausible once relevant listed patents become vulnerable or expire. The most defensible targets would be claims limited to:

• Particular ethanol concentrations.
• Specific HFA-134a/ciclesonide ratios.
• Canister or valve materials.
• Spray-performance ranges.
• Narrow dosing methods.

A challenger would face greater risk if the listed claims cover a tightly defined formulation and the reference product has a measurable performance signature that is difficult to reproduce outside the claim scope.

No current Paragraph IV settlement or active U.S. patent litigation is identified in the cited FDA materials. A transaction or launch decision should rely on the live Orange Book and PACER record rather than historical patent listings.

What commercial opportunities exist for Zetonna excipients?

Lower-emission reformulation

The clearest opportunity is a next-generation ciclesonide nasal aerosol using a lower-impact propellant. The product could target existing Zetonna users while reducing exposure to future propellant regulation and procurement constraints.

Authorized generic or contract manufacturing

A manufacturer with aerosol filling, valve assembly and analytical testing capacity could pursue an authorized generic, contract-manufacturing arrangement or regional supply deal. The asset is more attractive to companies that already produce pressurized inhalation or nasal products because facility qualification is expensive.

Combination nasal products

Ciclesonide could be evaluated in combination with an antihistamine or another nasal anti-inflammatory agent. The primary barriers would be combination-product clinical development, formulation compatibility, dose uniformity and intellectual-property separation. A combination product could compete with existing antihistamine-corticosteroid nasal sprays, but the clinical and regulatory investment would be materially higher than for a single-agent generic.

Pediatric and adherence-oriented devices

The approved Zetonna population begins at 12 years of age. A lower-actuation-force actuator, dose counter or simplified priming system could support pediatric or adherence-focused lifecycle management if supported by clinical and regulatory data.

Geographic expansion

The non-aqueous aerosol platform may be commercially useful in markets where preservative-free delivery, compact packaging or climate stability is valuable. Regional opportunities depend on local ciclesonide approvals, device registration, patent status, reimbursement and propellant policy.

How strong is the Zetonna patent estate?

The estate is strongest where formulation and device claims require a narrow combination of ciclesonide, ethanol, propellant, valve and performance parameters. It is weaker against a genuinely different delivery system, such as an aqueous pump spray, unless method-of-use claims remain enforceable and commercially relevant.

Patent strength should be scored across four dimensions:

Factor	Assessment
Active ingredient	Mature technology with limited long-term exclusivity value
Formulation	Potentially meaningful where composition ranges are narrow
Device	Potentially strong if actuator or valve claims are difficult to design around
Regulatory complexity	High relative to a standard nasal pump

The practical barrier may therefore be manufacturing know-how rather than patent duration. Stable aerosol filling, valve crimping, low-temperature processing, dose testing and extractables control can delay market entry even after core patents expire.

Key Takeaways

• Zetonna is a 37-mcg ciclesonide HFA nasal aerosol using HFA-134a and ethanol.
• Its principal technical value lies in the integrated drug-propellant-valve-actuator system.
• The leading lifecycle opportunity is a lower-global-warming-potential propellant reformulation.
• Generic developers face device-equivalence, plume, dose-uniformity and extractables challenges.
• Device and formulation claims may provide more commercial protection than the mature ciclesonide active-ingredient estate.
• Combination therapy, pediatric usability and authorized-generic supply are the main commercial expansion paths.
• Current Orange Book and litigation records control any launch or licensing conclusion.

FAQs About Zetonna Excipient and Commercial Strategy

Is Zetonna preservative-free?

Zetonna’s labeled excipients are HFA-134a and ethanol. The non-aqueous pressurized system does not depend on the conventional preservative approach used in some aqueous nasal sprays.[1]

Can HFA-134a in Zetonna be replaced directly with HFA-152a?

No. A propellant substitution would require reformulation and redevelopment because vapor pressure, flammability, solubility, valve compatibility and spray performance would change.

Is Zetonna easier to copy than an aqueous ciclesonide nasal spray?

No. The formulation contains fewer excipients, but the pressurized drug-device system creates additional equivalence and manufacturing requirements.

Could Zetonna become an over-the-counter product?

An OTC pathway would require FDA-supported monograph or application-based authorization, an acceptable self-selection profile, labeling suitable for nonprescription use and evidence supporting the proposed population and dosing. Prescription status cannot be changed solely by modifying excipients.

What is the most valuable Zetonna lifecycle patent opportunity?

A lower-emission propellant system combined with a redesigned valve or actuator offers the strongest potential for differentiated formulation, device and manufacturing claims.

References

1. U.S. Food and Drug Administration. (2017). Zetonna (ciclesonide) nasal aerosol prescribing information. Sunovion Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2012). Zetonna approval package, NDA 202535. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2009). Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays: Guidance for industry. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2013). Metered dose inhaler and dry powder inhaler drug products: Chemistry, manufacturing, and controls documentation. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

6. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. U.S. Department of Commerce.